Universal Cancer Vaccine Candidate Shows Positive Long-Term Benefits
The leader in immunostimulatory cancer vaccines announced that it had published its long-term overall survival (OS) results from a Phase 1 trial evaluating the universal cancer vaccine candidate UV1 in combination with the checkpoint inhibitor, ipilimumab. This study was conducted in patients with malignant metastatic melanoma.
UV1 is an peptide-based vaccination that induces a specific response from T cells against the universal antigen of cancer, telomerase.
The UV1 vaccine candidate from Norway’s Ultimovacs ASA was published in Frontiers in Immunology on May 11, 2021. It met the primary endpoints for safety and tolerance.
Source:
https://www.precisionvaccinations.com/universal-cancer-vaccine-candidate-presents-positive-long-term-benefits
